This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: August 18, 2005
Last updated: June 7, 2011
Last verified: June 2011

Primary Objective:

  • The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit 1).

Secondary Objectives:

The secondary objectives of the study are:

  • To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit in patients with Sp detected in sputum specimen at the start of the study (Visit 1);
  • To compare the clinical cure rates achieved by each treatment group in the penicillin or erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp (SSp) population at the End of Therapy (EOT) and Test of Cure visits;
  • To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of Therapy visit on the presence of Streptococcus pneumoniae strains resistant to beta-lactams or macrolides in the sputum of patients with Sp detected at the start of the study (Visit 1);
  • To compare the clinical efficacy at the End of Therapy visit and safety at the Test of Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global" randomized population.

Condition Intervention Phase
Chronic Bronchitis Drug: telithromycin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Multicenter, Clinical Study to Compare the Effects of Telithromycin, Azithromycin and Cefuroxime Axetil on the Penicillin or Macrolide Resistance of Streptococcus Pneumoniae in Patients With Acute Exacerbation of Chronic Bronchitis

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Presence of PERSp in sputum of patients at the TOC visit in each treatment group and who were Sp positive in sputum at Visit 1.

Secondary Outcome Measures:
  • Assessment of clinical signs and symptoms of AECB at EOT visit for the global efficacy analysis population & at TOC visit for patients who were Sp positive in sputum at visit 1.Bacteriological data at EOT and TOC visits. Assessment of safety...

Estimated Enrollment: 5660
Study Start Date: January 2004
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients meeting all of the following criteria will be considered for enrollment into the study:

  • Outpatients, male or female, aged 35 years or older
  • Patients with a documented history of chronic bronchitis, characterized by cough and excessive sputum production for most days of at least three months for 2 consecutive years
  • Patients with a clinical diagnosis of acute exacerbation of chronic bronchitis (AECB), presumed due to bacterial infection based on increased sputum purulence with either increased dyspnea or sputum volume
  • Patients producing spontaneous sputum
  • Patients with three or less AECB in the previous 12 months

Exclusion Criteria:

Patients presenting with any of the following will not be included in the study:

  • Patients with a known diagnosis of bronchiectasis; cystic fibrosis; lung cancer or lung metastases; active pulmonary tuberculosis; or with suspected pneumonia.
  • Patients with present acute respiratory failure or patients requiring aggressive airway management
  • Hospitalized patients and patients from institutional care facilities
  • Patients treated with antibiotics within 14 days prior to enrollment
  • Patients who are receiving other medications, including systemic antimicrobial agents; or who have other disease conditions or infections that could interfere with the evaluation of drug efficacy or safety.
  • Patients with a concomitant condition (including clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease) making either implementation of the protocol or interpretation of the study results difficult
  • Patients with a progressively fatal disease, or life expectancy ≤ three months
  • Patients who have received any other investigational drug within 1 month prior to study entry, or have such treatment planned for the study period
  • Patients with a recent (within the previous three months) history of alcohol or drug abuse
  • Immunocompromised patients including, but not limited to: patients with known HIV infection (CD4 + <200/mm3); known neutropenia (<1500 neutrophils/mm3); chronic corticosteroid therapy (≥ 10mg/day prednisolone equivalent during at least three months); immunodepressant treatment within the previous six months; splenectomized patients or patients with known hyposplenia or asplenia.
  • Patients with mental conditions rendering them unable to understand the nature, scope, and possible consequences of the study
  • Patients unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and are unlikely to complete the study
  • Patients having received anti-pneumococcal immunization in the previous six months before study entry
  • Patients with suspected or known hypersensitivity to, or suspected serious adverse reactions to the study medication, or to ß-lactams or macrolide classes of antibiotics
  • Patients diagnosed with myasthenia gravis
  • Women who are breast-feeding or who are pregnant
  • Women who are of childbearing potential who do not agree to use an approved contraceptive method during the study
  • Patients with galactose intolerance, lactase deficiency or glucose-galactose malabsorption
  • Patients with a known history of long QTc syndrome (e.g., personal or family history of syncope or arrhythmia)
  • Patients treated within 2 weeks prior to study entry, or requiring treatment during study medication, with CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, phenobarbital, and St John's wort
  • Patients requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Patients known to have impaired hepatic function
  • Patients known to have impaired renal function
  • Patients already enrolled in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00132938

United States, New Jersey
Bridgewater, New Jersey, United States
Brussels, Belgium
Paris, France
Budapest, Hungary
Casablanca, Morocco
Barcelona, Spain
Megrine, Tunisia
Istanbul, Turkey
Sponsors and Collaborators
Study Director: Gilles Perdriset, MD Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00132938     History of Changes
Other Study ID Numbers: HMR3647A_4020
EudraCT # :2004-001412-30
Study First Received: August 18, 2005
Last Updated: June 7, 2011

Additional relevant MeSH terms:
Acute Disease
Bronchitis, Chronic
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017